Peania, October 24th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr. Athanasios...
Peania, June 29th 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 28.06.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....
Peania, February 9th, 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 07.02.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....
Peania, September 29th, 2017 – In the First Half of 2017, Lavipharm reports increased Consolidated Turnover mainly attributed to international sales, despite economic pressures, sustained regulatory constraints and decrease of the pharmaceutical market in Greece. At the same time, the sharp drop in loans and...
Recession and instability features were evident in the Greek economy during 9M 2012, while in Healthcare, variability and constant changes influenced the whole sector. Within this negative business environment, Lavipharm focused on enhancing its export activity and strengthening its competitiveness, through the further decrease of...
During H1 2012, in an environment characterized by a political instability and recession rates, Lavipharm focused on enhancing its export activities, sustaining its market shares and strengthening its competitiveness while reducing operational costs and increasing productivity. In H1 2012, consolidated financial results were significantly affected by...
During the first quarter of 2012, in an extremely unstable and uncertain economic and political environment, Lavipharm followed a long-term plan to increase productivity and enhance its export activities. At the same time, Lavipharm continued to strengthen its extroversion and to seek new opportunities and...
Lavipharm has entered into a cooperation agreement with the Belgian medical plant specialist Tilman in the sector of plant based pharmaceutical products. Tilman is one of the largest companies in Europe and its plant originated products are marketed in 30 countries around the world. Tilman laboratories, established 50 years...
In this environment, Lavipharm mainly focused on the enhancement of its export activities. At the same time, despite the constant twists and instability that prevailed and obstructed the business plans, the Company followed a long-term plan to boost sales in the domestic market and to...
In a difficult financial environment, with constant changes in the legal framework of the health sector, and especially in pharmaceuticals, Lavipharm has further strengthened its extrovert activities, aiming to an even greater growth of exports. At the same time, the company implemented its long-term plan to...
